ANZCTR search results

The aim of this study is to examine the feasibility and impact of implementing a work-site based walking intervention on daily ambulatory activity (work day step counts), health status and work-ability of older workers performing predominately sedentary work.

This study is examining if the use of a PET probe during surgery for DCIS or breast cancer can accurately determine if all of the cancer cells have been removed. Currently 20% of patients require a second operation due to potential remaining cancer cells in the breast. Identification of these cells at the time of the first operation may reduce the number of women requiring second operations. This will have an impact on the patient (time & distress) and the health care system.

The purpose of this study is to assess a new orthodontic appliance which moves the lower jaw forward in a stepwise fashion. It is intended that the orthodontic appliance will be more comfortable than other appliances as it is less bulky and will result in a better physiological response because of the stepwise advancement of the lower jaw.

The overall design of ACCEPT for the purposes of the Department of Health and Ageing (DoHA) contract has been finalised and approved by ethics committees. The trial uses a cluster randomised controlled trial (RCT) design. Cluster randomisation is required because chlamydia is an infectious disease; randomising a group of people in the same geographic area (postcode) will allow the intervention to be delivered to people within the same social/sexual networks. The intervention aims to maximise the rate of regular chlamydia testing in people in the target age group who attend primary care services. The intervention will be randomised at the postcode level and all GP clinics and Aboriginal Community Controlled Health Services (ACCHS) in each postcode (estimated at 2-3 clinics on average) will be invited to participate. Overall, about 80% of postcodes will be selected from rural/regional areas based on the Rural, Remote and Metropolitan Areas classification (RRMA 3-7) so that the intervention can be applied to whole communities of people more likely to be in the same social/sexual network. Further, because young people often attend multiple clinics, randomising postcodes in rural areas and recruiting all clinics in the postcode, will allow the intervention to be applied to whole communities and facilitate data collection. The fundamental premise of this trial is that increased levels of testing can be achieved by providing a supportive intervention and that once levels of testing are increased high enough (more than 30%), the prevalence of chlamydia will fall.

The project aims to examine changes in glycosylated haemoglobin (which signifies stability of diabetes), physical, psychological and cognitive functioning following commencement of CSII therapy specifically measuring these parameters at three and six-month follow-up. The effect of CSII will be measured via routine blood tests, questionnaires examining physical health-related Quality of life (HRQoL), diabetes specific questions, psychological well-being and cognitive functioning. Patients will attend a review clinic at the Alfred specifically for CSII patients. Patients’ knowledge about their diabetes will be assessed pre and post CSII commencement (at several time points) using specific questionnaires and we will also measure glycaemic control via the recognized blood test of diabetes stability (HbA1c). The questionnaires used will include assessment of patients’ sense of empowerment, a self-care inventory on diabetes, a diabetes-specific treatment satisfaction questionnaire, and an emotional distress questionnaire that is diabetes specific. The aim is to assess whether CSII improves these aspects of an individual’s life with CSII. Within the project, we aim to set up a group pump review clinic for all patients commencing pump therapy at this hospital.

The purpose is to investigate whether the type of hand exercises affect short-term outcomes, in particular range of motion of the finger, following surgery to stabilise fractures of the proximal phalanx in the finger. Following surgery, participants will be randomised to one of two groups, where the treatment variable will be type of exercise. All other treatment will be constant between the two groups.

Prospective Randomized Observer Blinded Evaluation trial to determine the effect of adding colchicine 0.5mg/d to usual medical therapy in patients with proven coronary disease on the risk of future coronary events and stroke [unrelated to atrial fibrillation or intra-cranial hemorrhage]

Type 2 diabetes mellitus is a complex metabolic disorder characterized by abnormal insulin secretion and an abnormal glucose balance. The primary risk factor for developing type 2 diabetes mellitus is obesity, which can result in insulin resistance in the body. Insulin resistance is characterized by an impaired response to the physiologic effects of insulin, and leads to decreased cellular glucose uptake, increased hepatic gluconeogenesis and a compensatory increase in insulin secretion that contributes to beta-cell exhaustion. SYR-472 is being developed by Takeda Pharmaceutical Company Ltd. as an adjunct to diet and exercise to treat patients with type 2 diabetes mellitus. Medicinal products that prolong cardiac repolarization have been associated with a specific, potentially fatal polymorphic ventricular tachycardia called torsade de pointes. Although no evidence of cardiovascular effects have been noted in non-clinical studies of SYR-472 nor treatment-related trends revealed in phase 1 studies of SYR-472, this study is being conducted to investigate the effect of SYR-472 on electrocardiography in healthy adults, in compliance with the International Conference of Harmonization Tripartite Guideline: The clinical evaluation of QT/QTc (QT interval corrected for heart rate ) interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (ICH E14).

A 3-month intervention using encapsulated Caralluma fimbriata extract in combination with lifestyle intervention to investigate whether or not Caralluma fimbriata extract suppresses the appetite and decreases the risk factors of metabolic syndrome

This study will trial a Nurse-Led multidisciplinary (CVD) Risk Intervention Screening Clinic (NL-RISC) for cardiovascular disease that could be used as a model of care for risk factor modification in other settings. The proposed Nurse-led (CVD) Risk Intervention Screening Clinic (NL-RISC) is a unique, stand alone intervention designed to complement existing services. The model of care incorporates a specialist cardiac nurse trained in behavioural change, patient centred philosophies, the promotion of adherence to risk factor guidelines, strong multidisciplinary links, detailed patient assessment, and the use of a web-based support program. This study fits within preventive healthcare research framework as it aims to encourage those in the community with CVD to respond proactively to risk management interventions. At the broader level the NL-RISC will provide mentorship and facilitate the development of nurse clinicians and enhance continuity of care across interdisciplinary frameworks. The intention of the research team is to establish NL-RISC as a unique model of care for CVD in Australia and if proven effective for it to be translated into other healthcare settings. There is strong evidence for the screening and treatment of cardiovascular risk factors to reduce further cardiovascular events. Nurse-led risk factor assessment clinics provide the ideal opportunity to provide tailored risk factor management, and referral practices to improve adherence to national guidelines.